From multiplex serology to serolomics

• Verfasst von: Butt, Julia [VerfasserIn]
• Verfasst von: Murugan, Rajagopal [VerfasserIn]
• Verfasst von: Wenz, Theresa [VerfasserIn]
• Verfasst von: Olberg, Sylvia [VerfasserIn]
• Verfasst von: van Straaten, Monique [VerfasserIn]
• Verfasst von: Wardemann, Hedda [VerfasserIn]
• Verfasst von: Stebbins, Erec [VerfasserIn]
• Verfasst von: Kräusslich, Hans-Georg [VerfasserIn]
• Verfasst von: Bartenschlager, Ralf [VerfasserIn]
• Verfasst von: Brenner, Hermann [VerfasserIn]
• Verfasst von: Laketa, Vibor [VerfasserIn]
• Verfasst von: Schöttker, Ben [VerfasserIn]
• Verfasst von: Müller, Barbara [VerfasserIn]
• Verfasst von: Merle, Uta [VerfasserIn]
• Verfasst von: Waterboer, Tim [VerfasserIn]
• Titel: From multiplex serology to serolomics
• Titelzusatz: a novel approach to the antibody response against the SARS-CoV-2 proteome
• Verf.angabe: Julia Butt, Rajagopal Murugan, Theresa Hippchen, Sylvia Olberg, Monique van Straaten, Hedda Wardemann, Erec Stebbins, Hans-Georg Kräusslich, Ralf Bartenschlager, Hermann Brenner, Vibor Laketa, Ben Schöttker, Barbara Müller, Uta Merle and Tim Waterboer
• E-Jahr: 2021
• Jahr: 24 April 2021
• Umfang: 17 S.
• Fussnoten: Gesehen am 25.06.2021
• Titel Quelle: Enthalten in: Viruses
• Ort Quelle: Basel : MDPI, 2009
• Jahr Quelle: 2021
• Band/Heft Quelle: 13(2021), 5, Artikel-ID 749, Seite 1-17
• ISSN Quelle: 1999-4915
• DOI: doi:10.3390/v13050749
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: multiplex serology
• Sach-SW: SARS-CoV-2
• K10plus-PPN: 1761249894

Abstract

The emerging SARS-CoV-2 pandemic entails an urgent need for specific and sensitive high-throughput serological assays to assess SARS-CoV-2 epidemiology. We, therefore, aimed at developing a fluorescent-bead based SARS-CoV-2 multiplex serology assay for detection of antibody responses to the SARS-CoV-2 proteome. Proteins of the SARS-CoV-2 proteome and protein N of SARS-CoV-1 and common cold Coronaviruses (ccCoVs) were recombinantly expressed in E. coli or HEK293 cells. Assay performance was assessed in a COVID-19 case cohort (n = 48 hospitalized patients from Heidelberg) as well as n = 85 age- and sex-matched pre-pandemic controls from the ESTHER study. Assay validation included comparison with home-made immunofluorescence and commercial enzyme-linked immunosorbent (ELISA) assays. A sensitivity of 100% (95% CI: 86-100%) was achieved in COVID-19 patients 14 days post symptom onset with dual sero-positivity to SARS-CoV-2 N and the receptor-binding domain of the spike protein. The specificity obtained with this algorithm was 100% (95% CI: 96-100%). Antibody responses to ccCoVs N were abundantly high and did not correlate with those to SARS-CoV-2 N. Inclusion of additional SARS-CoV-2 proteins as well as separate assessment of immunoglobulin (Ig) classes M, A, and G allowed for explorative analyses regarding disease progression and course of antibody response. This newly developed SARS-CoV-2 multiplex serology assay achieved high sensitivity and specificity to determine SARS-CoV-2 sero-positivity. Its high throughput ability allows epidemiologic SARS-CoV-2 research in large population-based studies. Inclusion of additional pathogens into the panel as well as separate assessment of Ig isotypes will furthermore allow addressing research questions beyond SARS-CoV-2 sero-prevalence.